MY136696A - Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation - Google Patents

Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation

Info

Publication number
MY136696A
MY136696A MYPI20031367A MYPI20031367A MY136696A MY 136696 A MY136696 A MY 136696A MY PI20031367 A MYPI20031367 A MY PI20031367A MY PI20031367 A MYPI20031367 A MY PI20031367A MY 136696 A MY136696 A MY 136696A
Authority
MY
Malaysia
Prior art keywords
preparation
lyophilizing
pharmaceutical composition
liquid preparation
camptothecin derivative
Prior art date
Application number
MYPI20031367A
Other languages
English (en)
Inventor
Takahiro Ito
Shinji Narisawa
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MY136696A publication Critical patent/MY136696A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
MYPI20031367A 2002-04-16 2003-04-11 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation MY136696A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16

Publications (1)

Publication Number Publication Date
MY136696A true MY136696A (en) 2008-11-28

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20031367A MY136696A (en) 2002-04-16 2003-04-11 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation

Country Status (21)

Country Link
US (1) US20050215485A1 (enExample)
EP (1) EP1501549A2 (enExample)
JP (1) JP3927954B2 (enExample)
KR (1) KR100700963B1 (enExample)
CN (1) CN100544769C (enExample)
AR (1) AR039272A1 (enExample)
AU (1) AU2003223120B2 (enExample)
BR (1) BR0309283A (enExample)
CA (1) CA2480425A1 (enExample)
HR (1) HRP20040894A2 (enExample)
ME (1) MEP31308A (enExample)
MX (1) MXPA04010178A (enExample)
MY (1) MY136696A (enExample)
NO (1) NO20044964L (enExample)
PL (1) PL371677A1 (enExample)
RS (1) RS91204A (enExample)
RU (1) RU2315623C2 (enExample)
TW (1) TW200306314A (enExample)
UA (1) UA77295C2 (enExample)
WO (1) WO2003086471A2 (enExample)
ZA (1) ZA200408008B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556254A1 (en) * 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing camptothecins
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
JP6012902B1 (ja) 2014-12-26 2016-10-25 日本化薬株式会社 カンプトテシン類高分子誘導体の医薬製剤
EP3345654A4 (en) * 2015-09-03 2019-05-08 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING A CAMPTOTHECINPOLYMER DERIVATIVE
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
EP4438062A1 (en) * 2021-11-26 2024-10-02 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6815435B2 (en) * 2000-07-13 2004-11-09 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing DDS compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
AU2003223120A2 (en) 2003-10-27
RU2315623C2 (ru) 2008-01-27
CA2480425A1 (en) 2003-10-23
NO20044964L (no) 2004-11-15
UA77295C2 (en) 2006-11-15
KR100700963B1 (ko) 2007-03-28
TW200306314A (en) 2003-11-16
AU2003223120B2 (en) 2006-10-05
AU2003223120A1 (en) 2003-10-27
WO2003086471A3 (en) 2004-04-15
CN100544769C (zh) 2009-09-30
US20050215485A1 (en) 2005-09-29
MXPA04010178A (es) 2005-06-08
RU2004133349A (ru) 2005-05-27
HRP20040894A2 (en) 2005-10-31
JP2005523329A (ja) 2005-08-04
KR20050000516A (ko) 2005-01-05
CN1646172A (zh) 2005-07-27
BR0309283A (pt) 2005-02-15
RS91204A (sr) 2006-12-15
AR039272A1 (es) 2005-02-16
MEP31308A (en) 2010-10-10
WO2003086471A2 (en) 2003-10-23
EP1501549A2 (en) 2005-02-02
PL371677A1 (en) 2005-06-27
JP3927954B2 (ja) 2007-06-13
ZA200408008B (en) 2005-06-13

Similar Documents

Publication Publication Date Title
MY136696A (en) Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
CA2182244A1 (en) Camptothecin derivatives
CA2192725A1 (en) Camptothecin derivatives
AU5681800A (en) Quinoline derivatives as antibacterials
WO2001012233A3 (en) Sustained release formulation of a peptide
DE69912952D1 (en) Cyclosporine
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
BR0010520A (pt) Novos compostos farmaceuticamente ativos
GB0310919D0 (en) Pharmaceutical compositions
CA2457056A1 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
WO2007135117A3 (en) Soluble, stable insulin-containing formulations
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
TW200500369A (en) Cephem compounds
MY134325A (en) Quinoline derivatives
MXPA01011955A (es) Aminoacidos policiclicos, fusionados, como agentes farmaceuticos.
WO2006072000A3 (en) Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto
WO2008070049A8 (en) Peptide and treatment for hiv-1 infection
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
MX9603149A (es) Derivados de camptotecina.
EP1348444A3 (en) Sustained release formulation of a peptide complexed with a polymer